Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies

  • Kenichi Shikata
    Center for Innovative Clinical Medicine Okayama University Hospital Okayama Japan
  • Sadayoshi Ito
    Division of Nephrology, Endocrinology and Vascular Medicine Department of Medicine Tohoku University School of Medicine Sendai Japan
  • Naoki Kashihara
    Department of Nephrology and Hypertension Kawasaki Medical School Kurashiki Japan
  • Masaomi Nangaku
    Division of Nephrology and Endocrinology Graduate School of Medicine The University of Tokyo Tokyo Japan
  • Takashi Wada
    Department of Nephrology and Laboratory Medicine Kanazawa University Kanazawa Japan
  • Yasuyuki Okuda
    Data Intelligence Department Daiichi Sankyo Co., Ltd. Tokyo Japan
  • Tomoko Sawanobori
    Clinical Development Department Daiichi Sankyo Co., Ltd. Tokyo Japan
  • Kotaro Sugimoto
    Primary Medical Science Department Daiichi Sankyo Co., Ltd. Tokyo Japan

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims/Introduction</jats:title><jats:p>We evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum potassium elevation in Japanese patients with diabetic kidney disease.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>We carried out a prespecified subanalysis of data from two phase III studies: a multicenter, randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes and microalbuminuria (J308); and a multicenter, single‐arm, open‐label trial in patients with type 2 diabetes and macroalbuminuria (J309). Changes in serum potassium levels during the studies and other measures were evaluated according to SGLT2 inhibitor use.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In both studies, time‐course changes in serum potassium levels, and incidence rates of serum potassium elevation were lower in patients with co‐administration of SGLT2 inhibitor in both the placebo and esaxerenone groups than those without the inhibitor. In contrast, time‐course changes and mean percentage changes from baseline in urinary albumin‐to‐creatinine ratio, the proportion of patients with albuminuria remission and time‐course changes in blood pressure did not change with or without SGLT2 inhibitor, whereas the albumin‐to‐creatinine ratio and blood pressure were reduced with esaxerenone. The blood glucose‐lowering effect of SGLT2 inhibitor was not affected by esaxerenone.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In Japanese patients with type 2 diabetes and albuminuria treated with esaxerenone, concomitant use of SGLT2 inhibitor reduced the magnitude of serum potassium elevation without any change of its antihypertensive and albuminuria‐suppressing effects. Co‐administration of esaxerenone and SGLT2 inhibitor might be a beneficial treatment option for patients with diabetic kidney disease.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (37)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ